Page last updated: 2024-08-17

tributyrin and Neoplasms

tributyrin has been researched along with Neoplasms in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de Conti, A; Heidor, R; Moreno, FS; Ong, TP; Ortega, JF1
Takahashi, N1
Bauer, K; Chung, EJ; Edelman, MJ; Karp, J; Khanwani, S; Nemieboka, N; Tait, N; Trepel, J; Van Echo, D1
Conley, BA; Dover, G; Egorin, MJ; Fram, RJ; Rosen, DM; Sausville, EA; Tait, N; Van Echo, DA1

Reviews

2 review(s) available for tributyrin and Neoplasms

ArticleYear
Anticarcinogenic actions of tributyrin, a butyric acid prodrug.
    Current drug targets, 2012, Volume: 13, Issue:14

    Topics: Animals; Anticarcinogenic Agents; Butyric Acid; Cell Line, Tumor; Humans; Neoplasms; Prodrugs; Triglycerides

2012
[Induction of cell differentiation and development of new anticancer drugs].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2002, Volume: 122, Issue:8

    Topics: Acylation; Animals; Antineoplastic Agents; Cell Differentiation; Drug Design; Humans; Ketosteroids; Neoplasm Proteins; Neoplasms; Retinoids; Signal Transduction; Tretinoin; Triglycerides

2002

Trials

2 trial(s) available for tributyrin and Neoplasms

ArticleYear
Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug.
    Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:5

    Topics: Administration, Oral; Adult; Aged; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Treatment Outcome; Triglycerides

2003
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Prodrugs; Triglycerides

1998